A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.

导出 OA

翻译打印收藏纠错

作者： Pavani,Chalasani ^[1] ; Alison,Stopeck ^[2] ; Kathryn,Clarke ^[2] ; Robert,Livingston ^[2]

作者单位： University of Arizona Cancer Center, Tucson, Arizona, USA pchalasani@uacc.arizona.edu. ^[1] University of Arizona Cancer Center, Tucson, Arizona, USA. ^[2]

主题词老年人(Aged);老年人, 80以上(Aged, 80 and over);雄二烯类(Androstadienes);抗肿瘤药(Antineoplastic Agents);乳腺肿瘤(Breast Neoplasms);抗药性, 肿瘤(Drug Resistance, Neoplasm);雌二醇(Estradiol);雌激素受体调节剂(Estrogen Receptor Modulators);女(雌)性(Female);人类(Humans);中年人(Middle Aged);试点项目(Pilot Projects);绝经后期(Postmenopause);受体, 雌激素(Receptors, Estrogen);治疗结果(Treatment Outcome)

DOI 10.1634/theoncologist.2014-0306

PMID 25260365

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览97

The oncologist

2014年19卷11期

1127-8页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.

The oncologist

相似文献

The oncologist

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.

The oncologist

相似文献

The oncologist

相关期刊

检索历史清除